Literature DB >> 9460988

Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix.

A M Kersemaekers1, J Hermans, G J Fleuren, M J van de Vijver.   

Abstract

Loss of heterozygosity (LOH) frequently occurs in squamous cell carcinomas of the uterine cervix and indicates the probable sites of tumour-suppressor genes that play a role in the development of this tumour. To define the localization of these tumour-suppressor genes, we studied loss of heterozygosity in 64 invasive cervical carcinomas (stage IB and IIA) using the polymerase chain reaction with 24 primers for polymorphic repeats of known chromosomal localization. Chromosomes 3, 11, 13, 16 and 17, in particular, were studied. LOH was frequently found on chromosome 11, in particular at 11q22 (46%) and 11q23.3 (43%). LOH on chromosome 11p was not frequent. On chromosome 17p13.3, a marker (D17S513) distal to p53 showed 38% LOH, whereas p53 itself showed only 20% LOH. On the short arm of chromosome 3, LOH was frequently found (41%) at 3p21.1. The beta-catenin gene is located in this chromosomal region. Therefore, expression of beta-catenin protein was studied in 39 cases using immunohistochemistry. Staining of beta-catenin at the plasma membrane of tumour cells was present in 38 cases and completely absent in only one case. The tumour-suppressor gene on chromosome 3p21.1 may be beta-catenin in this one case, but (an)other tumour-suppressor gene(s) must also be present in this region. For the other chromosomes studied, 13q (BRCA-2) and 16q (E-cadherin), only sporadic losses (< 15% of cases) were found. Expression of E-cadherin was found in all of 37 cases but in six cases the staining was very weak. No correlation was found between clinical and histological parameters and losses on chromosome 3p, 11q and 17p. In addition to LOH, microsatellite instability was found in one tumour for almost all loci and in eight tumours for one to three loci. In conclusion, we have identified three loci with frequent LOH, which may harbour new tumour-suppressor genes, and found microsatellite instability in 14% of cervical carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9460988      PMCID: PMC2151237          DOI: 10.1038/bjc.1998.33

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  56 in total

1.  Stabilization of beta-catenin by genetic defects in melanoma cell lines.

Authors:  B Rubinfeld; P Robbins; M El-Gamil; I Albert; E Porfiri; P Polakis
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

2.  Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.

Authors:  R S Cornelis; M van Vliet; C B Vos; A M Cleton-Jansen; M J van de Vijver; J L Peterse; P M Khan; A L Børresen; C J Cornelisse; P Devilee
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

3.  Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus.

Authors:  K Jiko; H Tsuda; S Sato; S Hirohashi
Journal:  Int J Cancer       Date:  1994-12-01       Impact factor: 7.396

4.  Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples.

Authors:  J Isola; S DeVries; L Chu; S Ghazvini; F Waldman
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

5.  Allelotype analysis of cervical carcinoma.

Authors:  A B Mitra; V V Murty; R G Li; M Pratap; U K Luthra; R S Chaganti
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

6.  Genetic instability in human ovarian cancer cell lines.

Authors:  K Orth; J Hung; A Gazdar; A Bowcock; J M Mathis; J Sambrook
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

7.  PCR-RFLP studies on chromosome 3p in formaldehyde-fixed, paraffin-embedded cervical cancer tissues.

Authors:  F Karlsen; P H Rabbitts; V Sundresan; B Hagmar
Journal:  Int J Cancer       Date:  1994-09-15       Impact factor: 7.396

8.  Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development.

Authors:  C Kraus; T Liehr; J Hülsken; J Behrens; W Birchmeier; K H Grzeschik; W G Ballhausen
Journal:  Genomics       Date:  1994-09-01       Impact factor: 5.736

9.  Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL.

Authors:  P Devilee; E M van Schothorst; A F Bardoel; B Bonsing; N Kuipers-Dijkshoorn; M R James; G Fleuren; A G van der Mey; C J Cornelisse
Journal:  Genes Chromosomes Cancer       Date:  1994-10       Impact factor: 5.006

10.  E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton.

Authors:  J Hülsken; W Birchmeier; J Behrens
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

View more
  14 in total

1.  Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients.

Authors:  S Dasgupta; S B Chakraborty; A Roy; S Roychowdhury; C K Panda
Journal:  Mol Pathol       Date:  2003-10

2.  Loss of sequences on the short arm of chromosome 17 is a late event in squamous carcinoma of the cervix.

Authors:  C S Herrington; M Worsham; S A Southern; P Mackowiak; S R Wolman
Journal:  Mol Pathol       Date:  2001-06

3.  Characterization of genomic changes in the cervical pre-cancerous lesions and tumors induced by different types of human papillomaviruses.

Authors:  Petar Grozdanov; Savina Hadjidekova; Ivanka Dimova; Ivanka Nikolova; Draga Toncheva; Gancho Ganchev; Victor Zlatkov; Angel S Galabov
Journal:  Virusdisease       Date:  2016-08-09

Review 4.  Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer.

Authors:  B Clarke; R Chetty
Journal:  Mol Pathol       Date:  2002-02

5.  Assessment of the frequency of genetic alterations (LOH/MSI) in patients with intraepithelial cervical lesions with HPV infection: a pilot study.

Authors:  Monika Migdalska-Sęk; Agata Karowicz-Bilińska; Dorota Pastuszak-Lewandoska; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska-Senderowska; Justyna Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-04-18       Impact factor: 3.064

6.  Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q.

Authors:  Y Murakami; T Nobukuni; K Tamura; T Maruyama; T Sekiya; Y Arai; H Gomyou; A Tanigami; M Ohki; D Cabin; P Frischmeyer; P Hunt; R H Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer.

Authors:  Judith N Kloth; Jan Oosting; Tom van Wezel; Karoly Szuhai; Jeroen Knijnenburg; Arko Gorter; Gemma G Kenter; Gert Jan Fleuren; Ekaterina S Jordanova
Journal:  BMC Genomics       Date:  2007-02-20       Impact factor: 3.969

8.  N6-Methyladenosine Associated Silencing of miR-193b Promotes Cervical Cancer Aggressiveness by Targeting CCND1.

Authors:  Chunxian Huang; Jinxiao Liang; Shaodan Lin; Dongyan Wang; Qingsheng Xie; Zhongqiu Lin; Tingting Yao
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

9.  Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene.

Authors:  Ratnesh Kumar Singh; Dipanjana Indra; Sraboni Mitra; Ranajit Kumar Mondal; Partha Sarathi Basu; Anup Roy; Susanta Roychowdhury; Chinmay Kumar Panda
Journal:  Hum Genet       Date:  2007-05-22       Impact factor: 5.881

10.  Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions.

Authors:  Hugo Arias-Pulido; Gopeshwar Narayan; Hernan Vargas; Mahesh Mansukhani; Vundavalli V V S Murty
Journal:  Mol Cancer       Date:  2002-10-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.